# US 12,005,033 B2 · Compositions comprising mixtures of semifluorinated alkanes > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,005,033 B2 - Document ID: US12005033B2 - Status: Granted - Kind: B2 - Application number: 16/578,080 - Filed: 2019-09-20 - Published: 2020-06-18 - Granted: 2024-06-11 - Earliest claimed: 2012-09-12 - Assignees: Novaliq GmbH - Applicants: Novaliq GmbH - Inventors: Bernhard Günther; Bastian Theisinger; Sonja Theisinger; Dieter Scherer - Web page: https://patentgrep.com/patent/US12005033B2 ## CPC - A61K 31/02: Halogenated hydrocarbons - A61K 9/0048: {Eye, e.g. artificial tears} - A61P 27/00: Drugs for disorders of the senses - A61P 27/02: Ophthalmic agents - A61P 27/04: Artificial tears; Irrigation solutions - A61K 47/06: Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The invention provides novel compositions comprising at least two or more semifluorinated alkanes. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue, such as for use in the treatment of keratoconjunctivitis sicca (dry eye) and/or meibomian gland dysfunction and symptoms associated therewith. The invention further provides kits comprising such compositions. ## Claims ### Claim 1 A method for the treatment of a disease or disorder selected from keratoconjunctivitis sicca, Sjogren syndrome, lacrimal gland insufficiency, meibomian gland disease, and/or meibomian gland dysfunction, comprising administering to a patient in need thereof a composition comprising: one semifluorinated alkane or two or more different semifluorinated alkanes, wherein said composition is free of a therapeutically effective amount of any pharmaceutically active drug substance useful for ophthalmic treatment wherein the composition is topically administered to an eye or ophthalmic tissue. ### Claim 2 (depends on 1) The method according to claim 1, wherein the disease or disorder is keratoconjunctivitis sicca (dry eye). ### Claim 3 (depends on 1) The method according to claim 1, wherein the disease or disorder is meibomian gland dysfunction. ### Claim 4 (depends on 3) The method according to claim 3, wherein the method is effective in solubilizing meibum lipids and removing abnormal and obstructive meibum from clogged meibomian gland ducts. ### Claim 5 (depends on 4) The method according to claim 4, wherein the meibomian gland ducts are clogged with viscous meibum secretions comprising polar and non-polar lipids, cholesterol, wax esters, acyl glycerides, free fatty acids, and/or phospholipids. ### Claim 6 (depends on 1) The method according to claim 1, wherein the composition mixes with and supplements the existing tear film lipid layer and/or forms a film over the corneal surface. ### Claim 7 (depends on 1) The method according to claim 1, wherein the composition is administered to the cornea, the conjunctiva, the upper eye lid, the lower eye lid, the eye lid margin, the meibomian gland ducts, and/or the eye lashes. ### Claim 8 (depends on 1) The method of claim 1, wherein each semifluorinated alkane has a refractive index between 1.29 and 1.35 at 20° C. ### Claim 9 (depends on 1) The method according to claim 1, wherein one semifluorinated alkane comprised in the composition is F6H8. ### Claim 10 (depends on 1) The method according to claim 1, wherein the composition comprises: a semifluorinated alkane of the formula F(CF2)n(CH2)mH, wherein n is an integer from the range of 3 to 8 and m is an integer from the range of 3 to 10, and/or a semifluorinated alkane of the formula F(CF2)n(CH2)mH, wherein n is an integer from the range of 6 to 20 and m is an integer from the range of 10 to 20. ### Claim 11 (depends on 1) The method according to claim 1, wherein the weight ratio of the first semifluorinated alkane to the second semifluorinated alkane is at least about 3:1. ### Claim 12 A method for the treatment of a disease or disorder selected from keratoconjunctivitis sicca, Sjogren syndrome, lacrimal gland insufficiency, meibomian gland disease, and/or meibomian gland dysfunction, comprising administering to a patient in need thereof a composition comprising at least a first semifluorinated alkane of the formula F(CF2)n(CH2)mH, wherein n is an integer from the range of 3 to 8 and m is an integer from the range of 3 to 10, and a second semifluorinated alkane which is different than the first, wherein said composition is free of a therapeutically effective amount of any pharmaceutically active drug substance useful for ophthalmic treatment, wherein the composition is topically administered to an eye or ophthalmic tissue. ### Claim 13 (depends on 12) The method according to claim 12, wherein the weight ratio of the first semifluorinated alkane to the second semifluorinated alkane is at least about 3:1. ### Claim 14 (depends on 12) The method according to claim 12, wherein one semifluorinated alkane comprised in the composition is F6H8. ### Claim 15 (depends on 12) The method according to claim 12, wherein the second semifluorinated alkane has the formula F(CF2)n(CH2)mH, wherein n is an integer from the range of 6 to 20 and m is an integer from the range of 10 to 20. ### Claim 16 (depends on 12) The method according to claim 12, wherein the disease or disorder is keratoconjunctivitis sicca (dry eye). ### Claim 17 A method for the treatment of a disease or disorder selected from keratoconjunctivitis sicca, Sjogren syndrome, lacrimal gland insufficiency, meibomian gland disease, and/or meibomian gland dysfunction, comprising administering to a patient in need thereof a composition comprising at least two different semifluorinated alkanes, wherein the first semifluorinated alkane is selected from the group consisting of F(CF2)4(CH2)5H, F(CF2)4(CH2)6H, F(CF2)6(CH2)4H, F(CF2)6(CH2)6H, F(CF2)6(CH2)8H, and F(CF2)6(CH2)10H, and/or the second semifluorinated alkane is selected from the group consisting of F(CF2)8(CH2)10H and F(CF2)10(CH2)12H, wherein said composition is free of a therapeutically effective amount of any pharmaceutically active drug substance useful for ophthalmic treatment, wherein the composition is topically administered to an eye or ophthalmic tissue. ### Claim 18 (depends on 17) The method according to claim 17, wherein one semifluorinated alkane comprised in the composition is F6H8. ### Claim 19 A method for the treatment of a disease or disorder selected from keratoconjunctivitis sicca, Sjogren syndrome, lacrimal gland insufficiency, meibomian gland disease, and/or meibomian gland dysfunction, comprising administering to a patient in need thereof a composition comprising one semifluorinated alkane or two or more different semifluorinated alkanes, wherein each semifluorinated alkane is independently a linear alkane or a branched alkane, some of whose hydrogen atoms have been replaced by fluorine, wherein said composition is free of a therapeutically effective amount of any pharmaceutically active drug substance useful for ophthalmic treatment, wherein the composition is topically administered to an eye or ophthalmic tissue. ### Claim 20 (depends on 19) The method according to claim 19, wherein one semifluorinated alkane comprised in the composition is F6H8. ### Claim 21 (depends on 19) The method according to claim 19, wherein the weight ratio of the first semifluorinated alkane to the second semifluorinated alkane is at least about 3:1. ### Claim 22 (depends on 19) The method according to claim 19, wherein the disease or disorder is keratoconjunctivitis sicca (dry eye). ### Claim 23 (depends on 8) A method for the treatment of a disease or disorder selected from keratoconjunctivitis sicca, Sjogren syndrome, lacrimal gland insufficiency, meibomian gland disease, and/or meibomian gland dysfunction, comprising administering to a patient in need thereof a composition comprising at least two different semifluorinated alkanes, wherein the first semifluorinated alkane is F6H8, and wherein the second semifluorinated alkane is a linear or branched semifluorinated alkane, wherein said composition is free of a therapeutically effective amount of any pharmaceutically active drug substance useful for ophthalmic treatment, according to claim 8, wherein the composition is topically administered to an eye or ophthalmic tissue. ### Claim 24 (depends on 23) The method according to claim 23, wherein the weight ratio of the first semifluorinated alkane to the second semifluorinated alkane is at least about 3:1.